Combined immunotherapy with dendritic cells and cytokine-induced killer cells for solid tumors: a systematic review and meta-analysis of randomized controlled trials
Abstract Background Immunotherapy utilizing dendritic cells (DCs) and cytokine-induced killer (CIK) cells is a promising treatment approach for solid tumors. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of DC-CIK immunotherapy by assessing overall survival, prog...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-12-01
|
| Series: | Journal of Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12967-024-05940-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846112175477751808 |
|---|---|
| author | Wendi Jiang Zhongda Wang Qinghuizi Luo Zhe Dai Jialong Zhu Xiaoyue Tao Yiyang Xie Yuanyang Du Longwei Jiang Xiaoyuan Chu Gongbo Fu Zengjie Lei |
| author_facet | Wendi Jiang Zhongda Wang Qinghuizi Luo Zhe Dai Jialong Zhu Xiaoyue Tao Yiyang Xie Yuanyang Du Longwei Jiang Xiaoyuan Chu Gongbo Fu Zengjie Lei |
| author_sort | Wendi Jiang |
| collection | DOAJ |
| description | Abstract Background Immunotherapy utilizing dendritic cells (DCs) and cytokine-induced killer (CIK) cells is a promising treatment approach for solid tumors. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of DC-CIK immunotherapy by assessing overall survival, progression-free survival, overall response rate, disease control rate, and adverse events in relevant randomized controlled trials. The results of this analysis will contribute to optimizing treatment strategies and improving cancer immunotherapy outcomes. Method This systematic review and meta-analysis adhered to PRISMA guidelines. A comprehensive search was conducted on multiple databases for RCTs studying the combination of DC-CIK immunotherapy for solid tumors. Inclusion criteria were RCTs comparing DC-CIK immunotherapy with control therapy and reporting OS, PFS, ORR, or DCR. Two authors independently performed study selection and data extraction, with disagreements resolved through consensus or consultation with a third reviewer. Extracted data included study characteristics, participant information, interventions, outcomes, and quality assessment. Statistical analysis was performed using Review Manager and Stata software. Heterogeneity was assessed using chi-square and I-squared statistics. Sensitivity analysis and assessment of publication bias were planned. Results A total of 1013 records were initially retrieved, and after a thorough screening process, 13 randomized controlled trials (RCTs) were included in the meta-analysis. These studies involved a total of 1443 patients, with 730 receiving DC-CIK immunotherapy and 713 in the control groups. The included studies covered various cancer types, with the majority conducted in mainland China. The meta-analysis showed that DC-CIK immunotherapy was associated with improved overall survival (OS) and progression-free survival (PFS) compared to control therapy. Furthermore, DC-CIK immunotherapy demonstrated higher overall response rate (ORR) and disease control rate (DCR) compared to non-DC-CIK therapy. Adverse events were reported in both groups, with fever being more common in the DC-CIK immunotherapy group and bone marrow suppression and gastrointestinal reactions more common in the control group. Sensitivity analyses confirmed the stability of the results, while publication bias was observed for PFS and fever. Conclusions DC-CIK immunotherapy shows promising efficacy and safety for solid tumors, improving survival rates and response rates. Further research is needed to optimize treatment regimens and identify predictive factors. |
| format | Article |
| id | doaj-art-2c05203cb4ad43c98d687b6ec07f7264 |
| institution | Kabale University |
| issn | 1479-5876 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Translational Medicine |
| spelling | doaj-art-2c05203cb4ad43c98d687b6ec07f72642024-12-22T12:44:30ZengBMCJournal of Translational Medicine1479-58762024-12-0122111510.1186/s12967-024-05940-yCombined immunotherapy with dendritic cells and cytokine-induced killer cells for solid tumors: a systematic review and meta-analysis of randomized controlled trialsWendi Jiang0Zhongda Wang1Qinghuizi Luo2Zhe Dai3Jialong Zhu4Xiaoyue Tao5Yiyang Xie6Yuanyang Du7Longwei Jiang8Xiaoyuan Chu9Gongbo Fu10Zengjie Lei11Department of General Surgery, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing UniversityDepartment of Oncology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing UniversityDepartment of Oncology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing UniversityDepartment of Oncology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing UniversityDepartment of Oncology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing UniversityDepartment of Oncology, Jinling Clinical Medical College, Nanjing University of Chinese MedicineDepartment of Oncology, Jinling Clinical Medical College, Nanjing University of Chinese MedicineDepartment of Oncology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing UniversityDepartment of Oncology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing UniversityDepartment of Oncology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing UniversityDepartment of Oncology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing UniversityDepartment of Oncology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing UniversityAbstract Background Immunotherapy utilizing dendritic cells (DCs) and cytokine-induced killer (CIK) cells is a promising treatment approach for solid tumors. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of DC-CIK immunotherapy by assessing overall survival, progression-free survival, overall response rate, disease control rate, and adverse events in relevant randomized controlled trials. The results of this analysis will contribute to optimizing treatment strategies and improving cancer immunotherapy outcomes. Method This systematic review and meta-analysis adhered to PRISMA guidelines. A comprehensive search was conducted on multiple databases for RCTs studying the combination of DC-CIK immunotherapy for solid tumors. Inclusion criteria were RCTs comparing DC-CIK immunotherapy with control therapy and reporting OS, PFS, ORR, or DCR. Two authors independently performed study selection and data extraction, with disagreements resolved through consensus or consultation with a third reviewer. Extracted data included study characteristics, participant information, interventions, outcomes, and quality assessment. Statistical analysis was performed using Review Manager and Stata software. Heterogeneity was assessed using chi-square and I-squared statistics. Sensitivity analysis and assessment of publication bias were planned. Results A total of 1013 records were initially retrieved, and after a thorough screening process, 13 randomized controlled trials (RCTs) were included in the meta-analysis. These studies involved a total of 1443 patients, with 730 receiving DC-CIK immunotherapy and 713 in the control groups. The included studies covered various cancer types, with the majority conducted in mainland China. The meta-analysis showed that DC-CIK immunotherapy was associated with improved overall survival (OS) and progression-free survival (PFS) compared to control therapy. Furthermore, DC-CIK immunotherapy demonstrated higher overall response rate (ORR) and disease control rate (DCR) compared to non-DC-CIK therapy. Adverse events were reported in both groups, with fever being more common in the DC-CIK immunotherapy group and bone marrow suppression and gastrointestinal reactions more common in the control group. Sensitivity analyses confirmed the stability of the results, while publication bias was observed for PFS and fever. Conclusions DC-CIK immunotherapy shows promising efficacy and safety for solid tumors, improving survival rates and response rates. Further research is needed to optimize treatment regimens and identify predictive factors.https://doi.org/10.1186/s12967-024-05940-yDendritic cellsCytokine-induced killer cellsSolid tumorsCombined immunotherapy |
| spellingShingle | Wendi Jiang Zhongda Wang Qinghuizi Luo Zhe Dai Jialong Zhu Xiaoyue Tao Yiyang Xie Yuanyang Du Longwei Jiang Xiaoyuan Chu Gongbo Fu Zengjie Lei Combined immunotherapy with dendritic cells and cytokine-induced killer cells for solid tumors: a systematic review and meta-analysis of randomized controlled trials Journal of Translational Medicine Dendritic cells Cytokine-induced killer cells Solid tumors Combined immunotherapy |
| title | Combined immunotherapy with dendritic cells and cytokine-induced killer cells for solid tumors: a systematic review and meta-analysis of randomized controlled trials |
| title_full | Combined immunotherapy with dendritic cells and cytokine-induced killer cells for solid tumors: a systematic review and meta-analysis of randomized controlled trials |
| title_fullStr | Combined immunotherapy with dendritic cells and cytokine-induced killer cells for solid tumors: a systematic review and meta-analysis of randomized controlled trials |
| title_full_unstemmed | Combined immunotherapy with dendritic cells and cytokine-induced killer cells for solid tumors: a systematic review and meta-analysis of randomized controlled trials |
| title_short | Combined immunotherapy with dendritic cells and cytokine-induced killer cells for solid tumors: a systematic review and meta-analysis of randomized controlled trials |
| title_sort | combined immunotherapy with dendritic cells and cytokine induced killer cells for solid tumors a systematic review and meta analysis of randomized controlled trials |
| topic | Dendritic cells Cytokine-induced killer cells Solid tumors Combined immunotherapy |
| url | https://doi.org/10.1186/s12967-024-05940-y |
| work_keys_str_mv | AT wendijiang combinedimmunotherapywithdendriticcellsandcytokineinducedkillercellsforsolidtumorsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT zhongdawang combinedimmunotherapywithdendriticcellsandcytokineinducedkillercellsforsolidtumorsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT qinghuiziluo combinedimmunotherapywithdendriticcellsandcytokineinducedkillercellsforsolidtumorsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT zhedai combinedimmunotherapywithdendriticcellsandcytokineinducedkillercellsforsolidtumorsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT jialongzhu combinedimmunotherapywithdendriticcellsandcytokineinducedkillercellsforsolidtumorsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT xiaoyuetao combinedimmunotherapywithdendriticcellsandcytokineinducedkillercellsforsolidtumorsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT yiyangxie combinedimmunotherapywithdendriticcellsandcytokineinducedkillercellsforsolidtumorsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT yuanyangdu combinedimmunotherapywithdendriticcellsandcytokineinducedkillercellsforsolidtumorsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT longweijiang combinedimmunotherapywithdendriticcellsandcytokineinducedkillercellsforsolidtumorsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT xiaoyuanchu combinedimmunotherapywithdendriticcellsandcytokineinducedkillercellsforsolidtumorsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT gongbofu combinedimmunotherapywithdendriticcellsandcytokineinducedkillercellsforsolidtumorsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT zengjielei combinedimmunotherapywithdendriticcellsandcytokineinducedkillercellsforsolidtumorsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials |